Big pharma’s scramble over the patent cliff will be costly
Groups will need to buy mature biotechs to replace revenue lost to generic competitors
Related reading
Healthcare companies set for deals spree as drug patents expire
A gathering of pharmaceutical executives comes as the sector has rebounded from uncertainty over Trump’s policies
Chinese drugmakers shift from copycats to global innovators
Reforms, faster development and lower costs have turbocharged growth
UK biotech keeps selling itself to America
A shortage of late-stage capital pushes the biggest prizes into US hands
Merck transforms itself through dealmaking as clock ticks on top-selling drug
Acquisitions fuel pharma group’s evolution as it prepares to lose patent protection on cancer drug Keytruda
Big Pharma is falling out of love with Britain
Life sciences should be a natural place to look for growth
Biotech rally mints huge profits for hedge funds
Wave of M&A fuels rally as big pharma groups hunt for blockbusters ahead of patent cliff